GT BIOPHARMA, INC. Stock Repurchased and Retired During Period, Shares
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- GT BIOPHARMA, INC. stock repurchased and retired during period, shares for the quarter ending 2022-12-31 was -281.30K shares.
- GT BIOPHARMA, INC. stock repurchased and retired during period, shares for the quarter ending 2022-09-30 was 0.00 shares.
- GT BIOPHARMA, INC. stock repurchased and retired during period, shares for the quarter ending 2022-06-30 was 0.00 shares.
- GT BIOPHARMA, INC. stock repurchased and retired during period, shares for the quarter ending 2022-03-31 was 291.00K shares.
- GT BIOPHARMA, INC. stock repurchased and retired during period, shares for fiscal 2022 was 9.70K shares.
| Period end | Stock Repurchased and Retired During Period, Shares 3 month | Stock Repurchased and Retired During Period, Shares 12 month |
|---|---|---|
| 2022-12-31 | -281.30K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-26 | 9.70K shares 10-K · filed 2024-03-26 |
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-10-31 | |
| 2022-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | |
| 2022-03-31 | 291.00K shares 10-Q · filed 2023-11-01 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| STANDARD BIOTOOLS INC. (LAB) | United States | $0.297B | 3.80 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |